HOUSTON, TEXAS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) today announced that its Board of Directors declared a cash distribution (the “Distribution”) in an amount equal to $3.25 per share of common stock, par value $0.001 per share (the “Common Stock”), held by the Company’s stockholders of record on October 30, 2024, which was the effective date of the Company’s previously-announced legal dissolution. The Company expects to pay the Distribution on or b ...

Dissolution and Liquidation Plan - Guardion Health Sciences filed a certificate of dissolution with the Delaware Secretary of State, effective October 30, 2024, as part of its Plan of Liquidation and Dissolution approved by stockholders on May 31, 2024 [1] - The company closed its stock transfer books on October 30, 2024, and stockholders ceased to have rights except for receiving distributions under the Plan and Delaware General Corporation Law [2] - Guardion expects to pay a liquidating dividend of approximately $3.25 per share to stockholders of record as of the Effective Date, though the timing and amount may vary due to factors like taxes, employee costs, and unanticipated liabilities [3] Post-Dissolution Activities - After the Effective Date, Guardion will not engage in business activities except to preserve remaining assets, wind down operations, and distribute assets in accordance with the Plan [4] - The company will continue to exist for three years post-dissolution, or longer if directed by the Delaware Court of Chancery, to settle business, dispose of property, discharge liabilities, and distribute remaining assets to stockholders [4] Regulatory Relief - Guardion has been granted relief by the SEC to indefinitely suspend its reporting obligations under the Securities Exchange Act of 1934 and will file a Form 15 to notify the suspension of its duty to file reports under Sections 13 and 15(d) of the Act [5] Forward-Looking Statements - The company's statements regarding its dissolution, liquidation, and reporting obligations are forward-looking and subject to uncertainties, risks, and changes in circumstances [6][7][8] - Factors that may impact the company's plans include the completion and timing of delisting, dissolution, and implementation of the Plan, as well as the ability to satisfy liabilities and distribute remaining assets to stockholders [7][8]

HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as ...

Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of signific ...

Core Points - Guardion Health Sciences, Inc. has completed the sale of its Viactiv business to Doctor's Best Inc. for a gross cash consideration of $17,200,000, resulting in net cash proceeds of $16,250,000 at closing [1] - The sale was approved by Guardion's stockholders during a Special Meeting held on May 23, 2024, and the meeting was reconvened on May 31, 2024, to adopt a Plan of Liquidation and Dissolution [2] - Following the sale, the Company has minimal operations and the Board of Directors has decided to proceed with voluntary dissolution and liquidation, although this decision can be abandoned if a more favorable transaction arises [3] Company Overview - Guardion Health Sciences, Inc. is a clinical nutrition company that provides a range of science-based, clinically-supported products aimed at meeting the health needs of consumers and healthcare professionals [5]

Adjourns Special Meeting to May 31, 2024 in order to Solicit Additional Proxies in Support of its Plan of Liquidation and Dissolution HOUSTON, TEXAS, May 23, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically- supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that its stockholders ap ...

HOUSTON, TEXAS, May 23, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically- supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced today that its stockholders approved the previously announced sale of its Viactiv business at a special meeting (the "Meeting") held earlier today. Following this a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Delaware 001-38861 47-4428421 (I.R.S. Employer Identification No.) Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 GUARDION HEALTH SCIENCES, INC. (State or other jurisdiction of incorporation) (Commission File Number) (Exact name of registrant as specified in its charter) ☐ Pre-commencement communications pursuant to Rul ...

-- Financial Results for the Three Months Ended March 31, 2024 -- Institutional Shareholder Services Issues Report Recommending that Institutional Stockholders Vote in Favor of All Proposals at the Upcoming Special Meeting of Stockholders on May 23, 2024 Financial highlights for the three months ended March 31, 2024 include the following: In addition, during and subsequent to the three months ended March 31, 2024, the Company implemented the following business initiatives: Total revenue was $2,999,645 for t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission File Number: 001-38861 GUARDION HEALTH SCIENCES, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-4428421 | | --- | -- ...